Skip to main content
Uncategorized

Intelligent Pharma signs its first two research contracts in USA

By 4 de March de 2011November 18th, 2020No Comments
< Back to news
 04.03.2011

Intelligent Pharma signs its first two research contracts in USA

Intelligent Pharma, a Spanish biotech company devoted to the development, marketing and use of new computational technologies for drug design located at the Barcelona Science Park, has signed its first two research contracts with a company from the United States. Silicon Valley (CA) based Sciclone Pharmaceuticals (NASDAQ: SCLN) is a revenue generating, China-centric speciality pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases.


After only four years since its founding, Intelligent Pharma leads the Spanish market of computer-assisted drug design services. Its major goal for 2011 is the complete internationalization of the company, as well as increasing its market share in Germany, Switzerland and the United States. Last April, Intelligent Pharma opened a new office in Heidelberg, Germany, and several projects are currently under development in the United Kingdom. The newly signed collaborations with SciClone Pharmaceuticals represent an important milestone for the expansion and development of Intelligent Pharma.

Recently, Intelligent Pharma has been awarded not only for being the most innovative company in the Catalan region of northern Spain (Emprendedor XXI) but also for being the company with the largest growth potential amongst all spin-offs which emerged from the University of Barcelona (Senen Vilaró).